Bioleaders Corporation (142760) — Cash Flow-to-Debt Ratio
Bioleaders Corporation (142760) has a Cash Flow-to-Debt Ratio of -0.10x as of March 2026, meaning its operating cash flow of ₩-1.19 Billion could theoretically repay 0% of its total liabilities (₩11.39 Billion) in one year. Explore Bioleaders Corporation (142760) long-term investment share to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Bioleaders Corporation Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Bioleaders Corporation across 11 annual periods. Also explore how large is Bioleaders Corporation's balance sheet for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Bioleaders Corporation (2015–2025)
Year-by-year debt coverage analysis for Bioleaders Corporation. For market capitalisation and broader financial context, see market cap of Bioleaders Corporation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.50x | ₩-5.97 Billion | ₩12.04 Billion | ▼ -2364.8% |
| 2024 | -0.02x | ₩-501.75 Million | ₩24.94 Billion | ▼ -104.3% |
| 2023 | 0.47x | ₩6.18 Billion | ₩13.28 Billion | ▲ +386.1% |
| 2022 | -0.16x | ₩-20.60 Billion | ₩126.73 Billion | ▼ -364.0% |
| 2021 | -0.04x | ₩-5.04 Billion | ₩143.74 Billion | ▼ -3.4% |
| 2020 | -0.03x | ₩-5.43 Billion | ₩160.09 Billion | ▼ -91.9% |
| 2019 | -0.02x | ₩-2.20 Billion | ₩124.30 Billion | ▲ +73.9% |
| 2018 | -0.07x | ₩-8.77 Billion | ₩129.79 Billion | ▲ +98.1% |
| 2017 | -3.54x | ₩-8.53 Billion | ₩2.41 Billion | ▼ -90.7% |
| 2016 | -1.85x | ₩-7.70 Billion | ₩4.15 Billion | ▼ -53.1% |
| 2015 | -1.21x | ₩-4.83 Billion | ₩3.99 Billion | — |